The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first-degree relative with breast cancer

and the Hereditary Breast Cancer Clinical Study Group

doi:10.1111/cge.13191

The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first-degree relative with breast cancer

and the Hereditary Breast Cancer Clinical Study Group

Department of Preventive Medicine

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

The objective of this study was to estimate the lifetime risk of breast cancer in women with a BRCA1 or BRCA2 mutation with and without at least 1 first-degree relative with breast cancer. A total of 2835 women with a BRCA1 or BRCA2 mutation were followed. Age- and gene-specific breast cancer rates were calculated. The relative risks of breast cancer for subjects with a family history of breast cancer, compared to no family history were calculated. The mean age at baseline was 41.1 years, and they were followed for a mean of 6.0 years. The estimated penetrance of breast cancer to age 80 years was 60.8% for BRCA1 and 63.1% for BRCA2. For all BRCA carriers, the penetrance of breast cancer to age 80 for those with no first-degree relative with breast cancer was 60.4% and 63.3% for those with at least 1 first-degree relative with breast cancer. The risk of breast cancer for BRCA carriers with no first-degree relative with breast cancer is substantial, and as a result, clinical management for these women should be the same as those for women with an affected relative.

Original language	English (US)
Pages (from-to)	1063-1068
Number of pages	6
Journal	Clinical Genetics
Volume	93
Issue number	5
DOIs	https://doi.org/10.1111/cge.13191
State	Published - May 2018

All Science Journal Classification (ASJC) codes

Genetics
Genetics(clinical)

Access to Document

10.1111/cge.13191

Fingerprint Dive into the research topics of 'The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first-degree relative with breast cancer'. Together they form a unique fingerprint.

Cite this

@article{a7672b5c271a4760b19514d9ca98168a,

title = "The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first-degree relative with breast cancer",

abstract = "The objective of this study was to estimate the lifetime risk of breast cancer in women with a BRCA1 or BRCA2 mutation with and without at least 1 first-degree relative with breast cancer. A total of 2835 women with a BRCA1 or BRCA2 mutation were followed. Age- and gene-specific breast cancer rates were calculated. The relative risks of breast cancer for subjects with a family history of breast cancer, compared to no family history were calculated. The mean age at baseline was 41.1 years, and they were followed for a mean of 6.0 years. The estimated penetrance of breast cancer to age 80 years was 60.8% for BRCA1 and 63.1% for BRCA2. For all BRCA carriers, the penetrance of breast cancer to age 80 for those with no first-degree relative with breast cancer was 60.4% and 63.3% for those with at least 1 first-degree relative with breast cancer. The risk of breast cancer for BRCA carriers with no first-degree relative with breast cancer is substantial, and as a result, clinical management for these women should be the same as those for women with an affected relative.",

author = "{and the Hereditary Breast Cancer Clinical Study Group} and Metcalfe, {K. A.} and J. Lubinski and J. Gronwald and T. Huzarski and J. McCuaig and Lynch, {H. T.} and B. Karlan and Foulkes, {W. D.} and Singer, {C. F.} and Neuhausen, {S. L.} and L. Senter and A. Eisen and P. Sun and Narod, {S. A.}",

note = "Funding Information: Members of the Hereditary Breast Cancer Clinical Study Group: Joanne Kotsopoulos, Louise Bordeleau, Taya Fallen, Olufunmilayo Olopade, Charis Eng, Jeffrey N. Weitzel, Tuya Pal, Mary B. Daly, Siranoush Manoukian, Fergus Couch, Wendy McKinnon, Howard Saal, Jane McLennan, Edmond Lemire, Theodora Ross, Ava Kwong, Daniel Rayson, Dominique Stoppa Lyonnet, Barbara Pasini and Leanne Mercer. Publisher Copyright: {\textcopyright} 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd Copyright: Copyright 2018 Elsevier B.V., All rights reserved.",

year = "2018",

month = may,

doi = "10.1111/cge.13191",

language = "English (US)",

volume = "93",

pages = "1063--1068",

journal = "Clinical Genetics",

issn = "0009-9163",

publisher = "Wiley-Blackwell",

number = "5",

}

TY - JOUR

T1 - The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first-degree relative with breast cancer

AU - and the Hereditary Breast Cancer Clinical Study Group

AU - Metcalfe, K. A.

AU - Lubinski, J.

AU - Gronwald, J.

AU - Huzarski, T.

AU - McCuaig, J.

AU - Lynch, H. T.

AU - Karlan, B.

AU - Foulkes, W. D.

AU - Singer, C. F.

AU - Neuhausen, S. L.

AU - Senter, L.

AU - Eisen, A.

AU - Sun, P.

AU - Narod, S. A.

N1 - Funding Information: Members of the Hereditary Breast Cancer Clinical Study Group: Joanne Kotsopoulos, Louise Bordeleau, Taya Fallen, Olufunmilayo Olopade, Charis Eng, Jeffrey N. Weitzel, Tuya Pal, Mary B. Daly, Siranoush Manoukian, Fergus Couch, Wendy McKinnon, Howard Saal, Jane McLennan, Edmond Lemire, Theodora Ross, Ava Kwong, Daniel Rayson, Dominique Stoppa Lyonnet, Barbara Pasini and Leanne Mercer. Publisher Copyright: © 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd Copyright: Copyright 2018 Elsevier B.V., All rights reserved.

PY - 2018/5

Y1 - 2018/5

N2 - The objective of this study was to estimate the lifetime risk of breast cancer in women with a BRCA1 or BRCA2 mutation with and without at least 1 first-degree relative with breast cancer. A total of 2835 women with a BRCA1 or BRCA2 mutation were followed. Age- and gene-specific breast cancer rates were calculated. The relative risks of breast cancer for subjects with a family history of breast cancer, compared to no family history were calculated. The mean age at baseline was 41.1 years, and they were followed for a mean of 6.0 years. The estimated penetrance of breast cancer to age 80 years was 60.8% for BRCA1 and 63.1% for BRCA2. For all BRCA carriers, the penetrance of breast cancer to age 80 for those with no first-degree relative with breast cancer was 60.4% and 63.3% for those with at least 1 first-degree relative with breast cancer. The risk of breast cancer for BRCA carriers with no first-degree relative with breast cancer is substantial, and as a result, clinical management for these women should be the same as those for women with an affected relative.

AB - The objective of this study was to estimate the lifetime risk of breast cancer in women with a BRCA1 or BRCA2 mutation with and without at least 1 first-degree relative with breast cancer. A total of 2835 women with a BRCA1 or BRCA2 mutation were followed. Age- and gene-specific breast cancer rates were calculated. The relative risks of breast cancer for subjects with a family history of breast cancer, compared to no family history were calculated. The mean age at baseline was 41.1 years, and they were followed for a mean of 6.0 years. The estimated penetrance of breast cancer to age 80 years was 60.8% for BRCA1 and 63.1% for BRCA2. For all BRCA carriers, the penetrance of breast cancer to age 80 for those with no first-degree relative with breast cancer was 60.4% and 63.3% for those with at least 1 first-degree relative with breast cancer. The risk of breast cancer for BRCA carriers with no first-degree relative with breast cancer is substantial, and as a result, clinical management for these women should be the same as those for women with an affected relative.

UR - http://www.scopus.com/inward/record.url?scp=85044197589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044197589&partnerID=8YFLogxK

U2 - 10.1111/cge.13191

DO - 10.1111/cge.13191

M3 - Article

C2 - 29206279

AN - SCOPUS:85044197589

VL - 93

SP - 1063

EP - 1068

JO - Clinical Genetics

JF - Clinical Genetics

SN - 0009-9163

IS - 5

ER -